Literature DB >> 9519088

Costs of schizophrenia.

M Knapp1.   

Abstract

BACKGROUND: Schizophrenia is a common and burdensome illness, with implications not only for the health service but for a host of other care agencies--public and private--as well as for patients, families and the wider society.
METHOD: The paper reviews available UK evidence on the cost of schizophrenia (broadly defined) and on the cost-effectiveness of treatment options and alternative care arrangements. New evidence potentially alters our view of the costs of this illness.
RESULTS: Aggregating the identifiable direct and indirect costs of schizophrenia for England suggests an annual cost of 2.6 billion pounds, but even this sum omits some indirect impacts which cannot currently be costed. Just over half the identified total is accounted for by the direct costs falling to the NHS, local authorities, charities and the criminal justice system. In helping to tackle this cost burden, there is now a body of evidence on cost-effective community care arrangements, antipsychotic drugs and psychological interventions.
CONCLUSIONS: Although the costs of schizophrenia are considerable, there are treatments and care arrangements which can reduce this aggregate burden while maintaining or improving effectiveness.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9519088     DOI: 10.1192/bjp.171.6.509

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  32 in total

1.  How to manage the first episode of schizophrenia.

Authors:  S Frangou; P Byrne
Journal:  BMJ       Date:  2000-09-02

2.  The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study.

Authors:  Paul E Bebbington; Matthias Angermeyer; Jean-Michel Azorin; Traolach Brugha; Reinhold Kilian; Sonia Johnson; Mondher Toumi; Asa Kornfeld
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-09       Impact factor: 4.328

3.  Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?

Authors:  Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Economic aspects of peer support groups for psychosis.

Authors:  A D Stant; S Castelein; R Bruggeman; J T van Busschbach; M van der Gaag; H Knegtering; D Wiersma
Journal:  Community Ment Health J       Date:  2009-03-24

Review 6.  Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

7.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 8.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.

Authors:  Valentinas Maciulis; Istvan Bitter; Raimundas Milasiunas; Algirdas Dembinskas; Liaudminas Radavicius; Algirdas Kaunas; Martin Dossenbach; Daniel Walker
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

10.  Overview and emerging trends.

Authors:  Sandeep Grover; Ajit Avasthi; Subho Chakrabarti; Paramanand Kulhara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.